Radioresistance in rectal cancer: can nanoparticles turn the tide?
Abstract Rectal cancer accounts for over 35% of the worldwide colorectal cancer burden representing a distinctive subset of cancers from those arising in the colon. Colorectal cancers exhibit a continuum of traits that differ with their location in the large intestine. Due to anatomical and molecula...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-025-02232-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571963904622592 |
|---|---|
| author | Diogo Coelho Diogo Estêvão Maria José Oliveira Bruno Sarmento |
| author_facet | Diogo Coelho Diogo Estêvão Maria José Oliveira Bruno Sarmento |
| author_sort | Diogo Coelho |
| collection | DOAJ |
| description | Abstract Rectal cancer accounts for over 35% of the worldwide colorectal cancer burden representing a distinctive subset of cancers from those arising in the colon. Colorectal cancers exhibit a continuum of traits that differ with their location in the large intestine. Due to anatomical and molecular differences, rectal cancer is treated differently from colon cancer, with neoadjuvant chemoradiotherapy playing a pivotal role in the control of the locally advanced disease. However, radioresistance remains a major obstacle often correlated with poor prognosis. Multifunctional nanomedicines offer a promising approach to improve radiotherapy response rates, as well as to increase the intratumoral concentration of chemotherapeutic agents, such as 5-Fluorouracil. Here, we revise the main molecular differences between rectal and colon tumors, exploring the complex orchestration beyond rectal cancer radioresistance and the most promising nanomedicines reported in the literature to improve neoadjuvant therapy response rates. Graphical Abstract |
| format | Article |
| id | doaj-art-dfc44807bb2046ac821b5c589069c00c |
| institution | Kabale University |
| issn | 1476-4598 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj-art-dfc44807bb2046ac821b5c589069c00c2025-02-02T12:11:38ZengBMCMolecular Cancer1476-45982025-01-0124112310.1186/s12943-025-02232-xRadioresistance in rectal cancer: can nanoparticles turn the tide?Diogo Coelho0Diogo Estêvão1Maria José Oliveira2Bruno Sarmento3i3S - Instituto de Investigação e Inovação em Saúde, Universidade Do Portoi3S - Instituto de Investigação e Inovação em Saúde, Universidade Do Portoi3S - Instituto de Investigação e Inovação em Saúde, Universidade Do Portoi3S - Instituto de Investigação e Inovação em Saúde, Universidade Do PortoAbstract Rectal cancer accounts for over 35% of the worldwide colorectal cancer burden representing a distinctive subset of cancers from those arising in the colon. Colorectal cancers exhibit a continuum of traits that differ with their location in the large intestine. Due to anatomical and molecular differences, rectal cancer is treated differently from colon cancer, with neoadjuvant chemoradiotherapy playing a pivotal role in the control of the locally advanced disease. However, radioresistance remains a major obstacle often correlated with poor prognosis. Multifunctional nanomedicines offer a promising approach to improve radiotherapy response rates, as well as to increase the intratumoral concentration of chemotherapeutic agents, such as 5-Fluorouracil. Here, we revise the main molecular differences between rectal and colon tumors, exploring the complex orchestration beyond rectal cancer radioresistance and the most promising nanomedicines reported in the literature to improve neoadjuvant therapy response rates. Graphical Abstracthttps://doi.org/10.1186/s12943-025-02232-xRectal cancerTreatmentChemoradiotherapyRadioresistanceNanomedicines |
| spellingShingle | Diogo Coelho Diogo Estêvão Maria José Oliveira Bruno Sarmento Radioresistance in rectal cancer: can nanoparticles turn the tide? Molecular Cancer Rectal cancer Treatment Chemoradiotherapy Radioresistance Nanomedicines |
| title | Radioresistance in rectal cancer: can nanoparticles turn the tide? |
| title_full | Radioresistance in rectal cancer: can nanoparticles turn the tide? |
| title_fullStr | Radioresistance in rectal cancer: can nanoparticles turn the tide? |
| title_full_unstemmed | Radioresistance in rectal cancer: can nanoparticles turn the tide? |
| title_short | Radioresistance in rectal cancer: can nanoparticles turn the tide? |
| title_sort | radioresistance in rectal cancer can nanoparticles turn the tide |
| topic | Rectal cancer Treatment Chemoradiotherapy Radioresistance Nanomedicines |
| url | https://doi.org/10.1186/s12943-025-02232-x |
| work_keys_str_mv | AT diogocoelho radioresistanceinrectalcancercannanoparticlesturnthetide AT diogoestevao radioresistanceinrectalcancercannanoparticlesturnthetide AT mariajoseoliveira radioresistanceinrectalcancercannanoparticlesturnthetide AT brunosarmento radioresistanceinrectalcancercannanoparticlesturnthetide |